Surrozen, Inc./DE (SRZN) stock
SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$31.74+1.76 (+5.87%)
Close on Nov 18, 2026Market cap $373.06MP/E –Yield –
Surrozen net income
Net income is the profit left for shareholders after every expense, interest and tax.
Surrozen's net income for the twelve months ending Jun 30, 2026 was -$332.13M. For fiscal 2025 it was -$242.03M. The highest annual figure on record is -$32.72M in fiscal 2020.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$242.03M | – |
| FY2024 | Dec 31, 2024 | -$63.56M | – |
| FY2023 | Dec 31, 2023 | -$43.04M | – |
| FY2022 | Dec 31, 2022 | -$36.00M | – |
| FY2021 | Dec 31, 2021 | -$54.65M | – |
| FY2020 | Dec 31, 2020 | -$32.72M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $50.18M | +26.2% |
| Q1 FY2026 | Mar 31, 2026 | -$127.51M | – |
| Q4 FY2025 | Dec 31, 2025 | -$183.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$71.64M | – |
| Q2 FY2025 | Jun 30, 2025 | $39.75M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$28.04M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.43M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.91M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.45M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.30M | – |
| Q4 FY2022 | Dec 31, 2022 | -$775.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.93M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.95M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.95M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$12.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.02M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$8.64M | – |
See a number that looks wrong?